One third of the patients with DFS had an amputation of the lower extremity. Especially neuropathy or peripheral vascular disease was more prevalent in patients with DFS. New concepts to prevent DFS-induced amputations and to reduce cardiovascular risk factors before the occurrence of DFS are necessary.

Despite favourable 2-year outcomes, bariatric surgery is still used rarely in patients with T2DM and obesity. BMI rather than metabolic control seems to represent the major selector for or against bariatric surgery in T2DM.

Background: To describe checkpoint inhibitor-induced diabetes mellitus (CPI-DM) and to compare with regular type 1 (T1DM), type 2 (T2DM), and medication-induced diabetes mellitus (MI-DM).Methods: We included 88 177 adult patients from the Diabetes Patient Follow-Up (DPV) registry with diabetes manifestation between 2011 and 2020.Inclusion criteria were T1DM, T2DM, MI-DM, or CPI-DM. Because of the heterogeneity between the groups, we matched patients by age, sex, and diabetes duration using propensity scores. Patient data were aggregated in the respective first documented treatment year. Results: The matched cohort consisted of 24 164 patients; T1DM: 29, T2DM: 24000, MI-DM: 120, CPI-DM: 15 patients. Median age at manifestation of CPI-DM patients was 63.6 (57.2-72.8) years (53.3% male). Body mass index in CPI-DM patients was significantly lower (26.8 [23.9-28.1] kg/m 2 ) compared with T2DM patients (29.8 [26.2-34.3] kg/m 2 , P = 0.02). At manifestation, HbA1c was significantly higher in CPI-DM compared with MI-DM, but there

All data are shown as % of patients with fractures [lower confidence interval -upper confidence interval] adjusted for age, sex, diabetes duration, BMI and HbA1c (except the regression model for BMI).Numbers in bold face represent sub-groups that revealed significantly (p<0.05) more patients with fractures than at least one other subgroup. BMI = body-mass-index; HbA1c = haemoglobin A1c; DKA = diabetic ketoacidosis; Glin. = glinides; Sulfn. = sulphonylurea; SGLT2i = sodiumglucose transport protein 2 inhibitors; OAD-others = patients treated with any oral antidiabetic medication (except: glinides, sulphonylurea, SGLT2i

No abstract